Phase 3 Data Readout of EMPEROR Study to Come Earlier, With FDA Submission Expected to Follow | NeurologyLive
According to a new update from Stoke Therapeutics, data from the company’s massive, phase 3 EMPEROR trial (NCT06872125),…
Browsing Tag